Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
WU-KONG36: sunvozertinib plus pemetrexed/platinum after EGFR-TKI failure in EGFR-mutant advanced NSCLC
ChiCTR2400080629Phase 2Not yet recruiting
- Sponsor
- West China Hospital of Sichuan University
- Start
- Feb 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of sunvozertinib in non-small cell lung cancer (NSCLC), sponsored by West China Hospital of Sichuan University. Primary endpoint: Objective response rate. Planned start Feb 2024; status: not yet recruiting.
02
Drugs
sunvozertinib
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on ChiCTR2400080629.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400080629.